Opendata, web and dolomites

AcTaferon

Revitalizing the clinical potential of type I IFNs in fighting influenza A virus infections with AcTaferon.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 AcTaferon project word cloud

Explore the words cloud of the AcTaferon project. It provides you a very rough idea of what is the project "AcTaferon" about.

unveils    respectively    background    serious    vitro    broaden    company    activated    limited    pipeline    asset    transferred    orionis    miracle    influence    therapeutic    pandemics    regression    ifns    binding    severe    route    biological    epidemics    opportunity    fusing    cellular    intracellular    pilot    threat    interdisciplinary    actaferons    prof    interferon    mortality    viruses    surface    site    efficient    mutant    tumor    eacute    ing    combining    en    marker    ifn    co    actaferon    huge    industrial    antiviral    offers    vivo    negatively    saelens    remained    models    seasonal    drug    preliminary    clinical    regulate    too    tackle    viral    circumvents    substantial    doses    moiety    antitumor    desired    innovative    based    receptor    body    concentration    cytokine    limits    inactive    cells    affinity    fundamental    cancer    occasional    academic    influenza    drugs    obstacles    morbidity    causing    recognizes    diseases    strategy    effect    infection    hence    expertise    uz    administrable    fight    receptors    extend    underscore    interferons    health    sensitivity   

Project "AcTaferon" data sheet

The following table provides information about the project.

Coordinator
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS 

Organization address
address: RUE MICHEL ANGE 3
city: PARIS
postcode: 75794
website: www.cnrs.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website https://www.cordis.europa.eu/project/rcn/209395_en.html
 Total cost 144˙230 €
 EC max contribution 144˙230 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2016
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2017
 Duration (year-month-day) from 2017-05-01   to  2018-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS FR (PARIS) coordinator 144˙230.00

Map

 Project objective

Based on their antiviral and antitumor effect, type I interferons (IFNs) were believed to be the miracle drug to tackle viruses and cancer. However, clinical IFN applications remained limited due to severe side effects resulting from widespread cellular sensitivity to IFN, which limits the administrable doses. Hence, the drug concentration at the desired infection or tumor site is often too low to be fully therapeutic efficient. AcTaferon (Activated-by-Targeting interferon), co-developed by Prof. Uzé, circumvents these obstacles. By fusing an IFN mutant with strongly reduced receptor binding affinity to a targeting moiety that recognizes a surface marker on specific cells, AcTaferon remains inactive “en route” through the body and unveils its biological activity only on specific target cells. Robust tumor regression without side effects and preliminary antiviral effects underscore the huge clinical potential of AcTaferon to fight cancer and viral diseases. By combining the AcTaferon and influenza expertise of Prof. Uzé and Prof. Saelens, respectively, this interdisciplinary project offers the opportunity to broaden the innovative AcTaferon therapeutic strategy from the cancer to the viral infection field. Influenza A was selected as a pilot target as seasonal influenza A epidemics and occasional pandemics remain a serious health threat causing substantial morbidity and mortality. Influenza A-targeted AcTaferons will be developed and analyzed in relevant in vitro and in vivo models. Eventually, all knowledge will be transferred to Orionis, a company that will implement the AcTaferon technology to develop novel drugs. My background on the intracellular processes that negatively regulate cytokine receptors and hence influence the cellular sensitivity to a (therapeutic) cytokine is an asset to this project. I will be able to extend my fundamental research experience with applied cytokine research, which may extend into a new academic or industrial research pipeline.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ACTAFERON" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ACTAFERON" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

ICARUS (2020)

Information Content of locAlisation: fRom classical to qUantum Systems

Read More  

Cartesian Networks (2020)

Cartesian Networks in Early Modern Europe: A Quantitative and Interdisciplinary Approach

Read More  

CoCoNat (2019)

Coordination in constrained and natural distributed systems

Read More